



K063639

FEB 22 2007

### 510(k) Summary of Safety and Effectiveness

This summary of 510(k)-safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

#### Application Information:

Date Prepared: December 6, 2006  
Submitter: TissueLink Medical Inc.  
  
Address: One Washington Center Suite 400  
Dover, NH 03820  
  
Contacts: Vicki S. Anastasi  
Director of Regulatory Affairs  
Telephone Number: (603) 742-1515 ext. 210  
FAX Number: (603) 742-1488

#### Device Information:

Trade Name: Aquamantys SS4.0 Bipolar Sealer  
Common Name: Electrosurgery Bipolar Sealer  
Classification Name: Electrosurgical cutting and coagulation device and accessories -  
21CFR 878.4400

#### Predicate Devices:

Claim of Substantial Equivalence of the Aquamantys SS4.0 Bipolar Sealer is made to:

Name: Aquamantys 2.3 Bipolar Sealer  
510(k) Number: K#052859  
Regulation Number: 878-4400 Device, Electrosurgical, Cutting & Coagulation &  
Accessories  
Product Code: GEI  
Decision Date: October 25, 2005



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

TissueLink Medical, Inc.  
% Ms. Vicki S. Anastasi  
Director Regulatory Affairs  
One Washington Center, Suite 400  
Dover, New Hampshire 03820

FEB 22 2007

Re: K063639

Trade/Device Name: TissueLink Aquamantys SS4.0 Bipolar Sealer  
Regulation Number: 21 CFR 878.4400  
Regulation Name: Electrosurgical cutting and coagulation device and accessories  
Regulatory Class: II  
Product Code: GEI  
Dated: December 6, 2006  
Received: December 8, 2006

Dear Ms. Anastasi:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Ms. Vicki S. Anastasi

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Mark N. Melkerson". The signature is written in a cursive style with a large initial "M".

Mark N. Melkerson  
Director

Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

Indications for use Statement

Page \_\_\_\_ of \_\_\_\_

510(k) Number (if known): K063639

Device Name: TissueLink Aquamantys SS4.0 Bipolar Sealer

Indications for Use:

*The TissueLink SS4.0 bipolar sealer is a sterile, single-use bipolar electro-surgical device intended to be used in conjunction with the Aquamantys Pump Generator for delivery of RF energy and saline for hemostatic sealing and coagulation of soft tissue and bone at the operative site. It is intended for but not limited to orthopaedic, spine, endoscopic procedures, abdominal and thoracic surgery, and epidural vein sealing during surgery. The device is not intended for contraceptive tubal coagulation (permanent female sterilization.)*

Prescription Use X  
Use \_\_\_\_\_  
(Per 21 CFR 801.109)

OR

Over-The-Counter

Optional Format 1-

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)

Division of General, Restorative,  
and Neurological Devices

510(k) Number

K063639